Clinical

Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease, type 2 diabetes, and more.

Phase 3 ADORING data show tapinarof cream delivers early, consistent skin, itch, and sleep improvements in children with atopic dermatitis, with low adverse event rates.

Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability.

Panelists discuss how substituting LDL outcomes with statin-use metrics weakened cholesterol management quality.

Scientists restored the CCNA2 gene in adult human heart cells, enabling them to divide and form new functional cardiomyocytes—advancing heart repair therapies.

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.

Panelists discuss how shared decision-making empowers patients when choosing between IV and SC administration routes.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

The accelerated approval was based on a study that evaluated the efficacy in unresectable or metastatic nonsquamous NSCLC.

Previously treated patients with non–small cell lung cancer (NSCLC) saw durable results with andamertinib 240 mg.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

Panelists discuss how support networks and coordinated care are essential for delivering third-line metastatic colorectal cancer therapies effectively in the community.

Panelists discuss how addressing barriers and sharing real-world data can increase community confidence in prescribing third-line metastatic colorectal therapies.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Long-term nitrogen dioxide exposure raises ovarian cancer risk, underscoring the need for stricter air quality measures.

Women under 50 who consume high levels of ultraprocessed foods have a higher risk of developing early-onset conventional colorectal adenomas.

Lower-income countries rarely gain timely access to FDA-approved drugs tested in their populations, highlighting major global and ethical disparities.

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine.

Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.